Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

NCT07419932 · clinicaltrials.gov ↗

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer
Thyroid Neoplasms

Interventions

DRUG: Multitarget Tyrosine Kinase Inhibitors
DRUG: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
DRUG: RET Inhibitor
DRUG: PD(L)-1 inhibitor
PROCEDURE: Biopsy
PROCEDURE: Surgery
PROCEDURE: Surgery

Sponsor

Fujian Medical University